Page 55 - Multiple Sclerosis News Today

Race and MS status independently impact walking and physical performance, with Black patients experiencing worse health outcomes.

Australian researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment.

Background and purpose: Research promoting the health of the brain has increased exponentially over the last decade. The importance of ‘brain health’ for multiple sclerosis (MS), as one example, is a high priority. However, as research into the concept increases, so does varied use of the term. Methods: A scoping review, guided by the methodological framework of the Joanna Briggs Institute, was conducted to collate the evidence relating to brain health for MS. A comprehensive literature sear...

BioNxt Solutions Inc. reported that the toxicity study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis has been completed and results...

Hackensack Meridian Health is first in the tri-state area to implant Medtronics Percept RC DBS rechargable neurostimulator

Hackensack Meridian Health is first in the tri-state area to implant Medtronics Percept RC DBS rechargable neurostimulator

The Multiple Sclerosis Society of South Africa (MSSA) is thrilled to announce a groundbreaking achievement in gaining international recognition from the esteemed MS International Federation (MSIF).

Faith Bigam has been in and out of acute kidney failure and kidney damage about six times.

Clene Inc. (NASDAQ:CLNN – Get Free Report) has received a consensus rating of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is […]

Shares of Clene Inc. (NASDAQ:CLNN – Get Free Report) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock […]